ClinicalTrials.gg
CompletedNCT07634744Updated Sep 25, 2026

A Phase IIa Study in Primary IgA Nephropathy Patients

A Phase 2 interventional study of XH-S003 Capsule in IgA Nephropathy, sponsored by Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.. Completed at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-25.

Sponsored by Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. (part of Fosun Pharma) · Phase 2, Interventional, and Treatment

Updated Sep 25, 2026Sponsor changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
25
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 127 studies in Glomerulonephritis, IGA with a site in China — 58 open to participants now, 73 under way, 20 of them phase 3. Glomerulonephritis, IGA · China.

Enrollment
87th of 109
25 · median 84
Started
2024
with 11 others
Phase 2
27 of 127
14 open now
Registered
84th of 127
by date

Among the 127 studies in Glomerulonephritis, IGA with a site in China, this one is the 87th largest by enrollment of the 109 interventional ones that give a count, is one of 12 that started in 2024, is one of 27 in phase 2, and was the 84th registered.

Glomerulonephritis, IGA

276 studies on the registry are indexed under Glomerulonephritis, IGA; 108 are open to participants now.

Browse Glomerulonephritis, IGA studies →

Open to participants now

58 of the 127 studies in Glomerulonephritis, IGA with a site in China are open now. Recruiting first, the newest first:

53 more — sign in →

All 58 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 68 Glomerulonephritis, IGA studies recruiting now, 39 (57%) set no upper age limit and 24 (35%) stop at 75 or younger; 21 take children under 18; 5 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 127 studies in Glomerulonephritis, IGA with a site in China, or all of them as a file.
02

Study summary

This is a phase IIa, multicenter, single-arm, open-label study to evaluate the safety and efficacy of XH-S003 in patients with primary IgA nephropathy

03

Conditions studied

  • IgA Nephropathy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  • Subjects must meet the following inclusion criteria:

    ● Male and female patients aged ≥18 years with a renal -confirmed diagnosis of primary IgA nephropathy:

    1. For patients with (CKD-EPI) ≥ 45 mL/min/1.73m2 at screening, a renal pathology biopsy within 10 years confirmed primary IgA nephropathy;
    2. For screening, eGFR (CKD-EPI) ≥30 and \<45 mL/min/1.73m2 patients, within 2 years, diagnosed with primary IgA nephropathy through renal pathology biopsy;
    3. Renal pathology biopsy shows tubulointerstitial fibrosis \< 50%;
    4. Renal pathology biopsy shows crescent formation in \< 50% of glomeruli;
    5. If previous renal pathology biopsy results are unavailable, a biopsy needs to be performed during the screening period;

      • During screening and after completion of import eGFR (CKD-EPI) ≥ 30 mL/min/1.73 m2;
      • During screening and after completion of import, UPCR ≥ 0.75 g/g;
      • Before the first administration of medication, vaccination against Neisseria meningitidis and Streptococcus pneumoniae is required. If the patient has not been vaccinated before, or requires a booster, the vaccine should be administered at least 2 weeks prior to the first administration of medication. If the first administration of medication must begin earlier than 2 weeks after vaccination, prophylactic antibiotic therapy should be used until at least 2 weeks after vaccination;
      • Before the first administration, patients must have been on a stable treatment with the maximum tolerated dose of ACEi/ARB and SGLT2i for at least 90 days, and this treatment should remain unchanged during the study period. Additionally, if the patient is using diuretics or other antihypertensive treatments, the medication dosage should also be stable for at least 90 days before the first administration and remain unchanged during the study period;
      • After thoroughly understanding the nature, significance, potential benefits, possible inconveniences, and potential risks of the trial, and voluntarily participating in this clinical trial, the participant is able to communicate well with the researchers, comply with the requirements of the entire study, and has signed a written form.
      • Subjects of commit to having no plans for procreation, sperm or egg donation from screening to 1 month after the last dose (for females) or 3 months (for males), and voluntarily agree to use effective physical methods (including their partners).

      Exclusion Criteria:

  • Exclusion criteria include any of the following:

    • Secondary IgAN or those in whom secondary factors cannot be ruled out by investigator assessment;
    • Rapidly progressive IgA nephropathy (such as a decrease in eGFR (CKD-EPI) by ≥50% within 3 months, or less than 50% but with a risk of rapid decline in kidney function as assessed by the investigator);
    • Patients assessed by researchers to have other possible systemic diseases causing proteinuria (such as diabetic nephropathy, diseases, antineutrophil cytoplasmic antibody-associated vasculitis, etc.); or those with severe urinary tract obstruction or dysuria; or other chronic kidney diseases (with or without kidney failure);
    • Known or suspected coalescence of immune deficiency diseases, hereditary complement deficiency as assessed by the researcher;
    • Any organ transplant recipient (excluding corneal transplant);
    • According to the investigator's assessment, blood pressure was inadequately controlled at screening (sitting blood pressure systolic >150 mmHg or blood pressure diastolic >90 mmHg);
    • Used or other immunomodulatory drugs within 90 days prior to the first administration, or still within 5 half-lives of the drug, whichever is longer, specifically including but not limited to cyclophosphamide, rituximab, infliximab, eculizumab, canakinumab, Mycophenolate Mofetil, Ciclosporin, tacrolimus, sirolimus, everolimus, systemic , etc.
    • Patients who have been treated with Endothelin receptor antagonists within the first 90 days before initial medication;
    • Individuals who have taken any decocted herbal products or used Jinshuibao, Bailing capsules, Huangkui capsules, Chinese patent medicines with immunosuppressive action (such as Tripterygium wilfordii preparations, Sinomenium acutum preparations, etc.), or other herbal products/Chinese patent medicines assessed by the researcher to have an impact on the trial assessment within 90 days prior to the first medication;
    • Patients who have previously or are currently receiving oral budesonide sustained-release tablets (Nefecon®, Nifukang®) for the treatment of IgAN;
    • During screening, individuals who are currently using hydroxychloroquine but have unstable treatment (except those who have been on stable treatment for at least 3 months prior to the first administration and can maintain this treatment unchanged throughout the study) or those planning to start using hydroxychloroquine during the study;
    • Patients with coalescence of systemic major diseases, including but not limited to: advanced stage heart disorder (such as Class IV), severe lung disease (such as severe pulmonary arterial hypertension (WHO Class IV), active hepatitis, or other systemic major diseases deemed unsuitable for participation in this study by the investigator;
    • During screening, individuals with significantly abnormal liver function: any parameter of , AST, GGT, or alkaline phosphatase > 3 times the (ULN); serum total > 2 times ULN;14. Screening for (HIV) infection (HIV antibody positive), active syphilis infection, virus infection (hepatitis B surface antigen positive), active virus infection;
    • Active or latent tuberculosis during screening;
    • Individuals with a history of malignant neoplasm within the 5 years prior to screening (excluding carcinoma in situ and thyroid cancer that have been assessed by the researcher as having been radically resected);
    • History of Neisseria meningitidis infection;
    • Chronic active or recurrent infections within 1 year prior to screening, deemed unsuitable for participation in this study by the investigator, such as liver abscess, pyelonephritis, etc.;
    • Individuals with active systemic bacterial, viral (including COVID-19), or fungal infections requiring intravenous antibiotic treatment within 2 weeks prior to the first medication; those with an axillary body temperature >38°C within 7 days prior to the first medication;
    • Severe trauma or major surgery history within 3 months prior to screening, or plans to undergo major surgery during the trial;
    • History of blood donation or severe blood loss (blood volume ≥400mL) within 3 months prior to screening, or having received a transfusion within 3 months prior to screening;
    • Suspected or confirmed allergy to similar components of the drug product or any components within the investigational drug product;
    • Pregnant or lactating women, or those with a positive pregnancy test;
    • History of drug abuse or substance use.
    • History of alcoholism within the 6 months prior to screening (average weekly consumption of ≥14 units of alcohol: 1 unit = 285 mL of beer; or 25 mL of spirits; or 125 mL of wine);
    • Participated in other clinical investigational drug trials (or still within 5 half-lives of the drug, whichever is longer) or medical device clinical trials within 30 days prior to screening, or plans to participate in other clinical trials during the study period, or if the investigator's assessment indicates the presence of residual effects;
    • Subjects assessed by the researcher to have diseases or medical conditions that affect drug absorption, distribution, metabolism, and excretion or may reduce compliance, such as a history of severe intestinal diseases, major gastrointestinal surgery, or the presence of dysphagia;
    • Researchers believe that any condition that may prevent subjects from completing this study or pose significant risks to the subjects, or patients deemed unsuitable to participate in this study by the researchers
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
25 participants (actual)

Study arms

  • Experimental
    XH-S003 Capsule

    100mg and 25mg XH-S003 capsules QD Oral.

    Drug: XH-S003 Capsule

Interventions

  • DrugXH-S003 Capsule

    Oral, once daily

06

What researchers measure

Primary outcomes

  1. UPCR

    The ratio to baseline of UPCR (sampled from 24-hour urine collection) on Day 90 after the first drug administration.

    Time frame: Baseline and Day 90

Secondary outcomes

  1. UACR

    The ratio to baseline of UACR on Day 90 after the first drug administration

    Time frame: Baseline to Day 90

  2. UPE

    The ratio to baseline of UPE on Day 90 after the first drug administration

    Time frame: Baseline to Day 90

  3. UAE

    The ratio to baseline of UAE on Day 90 after the first drug administration

    Time frame: Baseline to Day 90

  4. eGFR

    eGFR change from baseline on Day 90 after the first drug administration.

    Time frame: Baseline to Day 90

  5. Serum Creatinine

    Change from baseline of serum creatinine

    Time frame: up to Day 90

07

Study locations

1 site
  • Peking University First Hospital
    Beijing, China
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2024 to primary completion in Apr 2026, 15 months.

Of 41 phase 2 interventional studies under Glomerulonephritis, IGA, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 50. This study's 15 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 27, 2025
First posted
Jun 9, 2026
StartActual
Dec 31, 2024
Primary completionActual
Apr 23, 2026
CompletionActual
Apr 23, 2026
Last update
Sep 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sponsor
S-INFINITY Pharmaceuticals Co., Ltd→Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
Sep 25, 2026
Show all 1 update
  1. Sep 25, 2026
    Sponsor S-INFINITY Pharmaceuticals Co., Ltd→Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
    + 1 other change: identifiers

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07634744
Responsible party
Sponsor
First posted
Jun 9, 2026
Start date
Dec 31, 2024
Primary completion
Apr 23, 2026
Completion
Apr 23, 2026
Last update
Sep 25, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion